Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose is a monosaccharide that provides a source of calories and hydration. It is metabolized to carbon dioxide and water, yielding energy. Sodium chloride provides electrolytes to maintain osmotic balance and fluid distribution.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Intravenous infusion for fluid and electrolyte replacement,Provision of caloric energy in parenteral nutrition
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion; dose depends on fluid and caloric needs, typically 100-200 m L/hour for maintenance in adults. Maximum infusion rate: 0.5 g/kg/hour dextrose.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Dextrose has a plasma half-life of approximately 1.5-2 hours under euglycemic conditions, prolonged in renal impairment (not directly applicable as it is continuously infused). Sodium and chloride have no defined half-life; they are handled by renal homeostatic mechanisms with kinetic parameters dependent on GFR and tubular function.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Dextrose is metabolized via glycolysis and the citric acid cycle to CO2 and water; sodium chloride is not metabolized.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Dextrose is completely metabolized to carbon dioxide and water; no significant renal excretion. Sodium and chloride are primarily excreted renally (99% of filtered load reabsorbed, with excess excreted in urine). Fecal/biliary elimination is negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Dextrose: negligible protein binding (<1%). Sodium and chloride: not protein bound; freely ionized.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Dextrose: Vd ~0.2 L/kg (confined to extracellular fluid and rapidly equilibrates with total body water). Sodium: Vd ~0.15-0.25 L/kg (primarily extracellular). Chloride: Vd ~0.2 L/kg (extracellular). These values indicate distribution mainly in the extracellular compartment.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intravenous: 100% bioavailability. Not administered by other routes.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
GFR >50 m L/min: no adjustment. GFR 10-50 m L/min: monitor fluid and electrolyte status; reduce rate if signs of fluid overload. GFR <10 m L/min: use with caution; consider alternative with lower sodium content; adjust rate based on fluid balance and serum sodium.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific adjustment for Child-Pugh class A or B; in class C, monitor glucose and electrolytes closely due to risk of hyperglycemia and fluid retention.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Intravenous infusion: neonates and children, 5 m L/kg/hour for maintenance; adjust based on serum glucose, electrolytes, and fluid status. Maximum dextrose infusion rate: 0.5 g/kg/hour.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Use with caution due to age-related decline in renal function; start at lower rates (e.g., 50-100 m L/hour) and titrate based on fluid status, serum glucose, and electrolytes; monitor for hyperglycemia and fluid overload.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None.
None.
Risk of hyperglycemia and hyperosmolar syndrome in patients with diabetes or glucose intolerance,Risk of fluid overload in patients with cardiovascular or renal impairment,Risk of electrolyte imbalances with prolonged use or large volumes,Do not administer unless solution is clear and container is intact
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to dextrose or sodium chloride,Hyperglycemia with coma,Severe hyponatremia or hypernatremia,Intracranial hemorrhage (if hypertonic solutions are used),Renal failure with oliguria or anuria
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No direct food interactions. However, the dextrose content may affect blood glucose levels; diabetic patients should monitor glucose closely. No dietary restrictions required for this intravenous solution.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
No known teratogenic risk. Dextrose and sodium chloride are physiologic components; hyperglycemia from high dextrose doses may be associated with fetal macrosomia and neonatal hypoglycemia in the third trimester.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Compatible with breastfeeding. Intravenous dextrose and sodium chloride are endogenous substances; M/P ratio not determined as they are not actively transferred into milk in significant amounts.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
No systematic dose adjustment required. However, pregnancy-induced increased plasma volume and glomerular filtration rate may reduce serum glucose and sodium concentrations; monitor and adjust infusion rate to maintain euglycemia and electrolyte balance.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
This solution provides 10% dextrose (100 g/L) and 0.11% sodium chloride (11 m Eq/L Na+, 11 m Eq/L Cl-). It is hypertonic (approx. 555 m Osm/L) and should be administered via central line if prolonged therapy to avoid thrombophlebitis. Use cautiously in patients with heart failure, renal impairment, or hyperglycemia. Monitor serum glucose and electrolytes. Do not administer simultaneously with blood products due to risk of hemolysis.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This intravenous fluid contains sugar (dextrose) and salt (sodium chloride).,It is used to provide calories and maintain fluid balance when you cannot eat or drink.,Report any signs of allergic reaction: rash, itching, difficulty breathing.,Tell your nurse if you experience headache, nausea, swelling, or rapid heartbeat.,Your blood sugar and electrolyte levels will be checked regularly during treatment.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose is a monosaccharide that provides a source of calories and hydration. It is metabolized to carbon dioxide and water, yielding energy. Sodium chloride provides electrolytes to maintain osmotic balance and fluid distribution.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is: Intravenous infusion; dose depends on fluid and caloric needs, typically 100-200 m L/hour for maintenance in adults. Maximum infusion rate: 0.5 g/kg/hour dextrose.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER is classified as Category A/B. No known teratogenic risk. Dextrose and sodium chloride are physiologic components; hyperglycemia from high dextrose doses may be associated with fetal macrosomia and neonatal hypo. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.